Back to Preclinical Safety
Novartis

Preclinical Safety

Patient safety is of paramount importance for any drug discovery program.  This course looks at some of the lessons learned which have influenced how promising molecules are currently evaluated for safety risks.  In vitro and in vivo toxicology and safety studies are discussed, why they are performed, and how the data they provide guide a safety risk assessment, including determining a therapeutic index or safety window for a drug.  Finally, the course will look at how safety data guide human dose selection, and some of the studies performed during clinical development. Target audience: This course is suitable for life scientists, clinicians, and individuals from fields that support drug discovery (e.g., patents, finance, licensing, etc.) interested in learning more about the pharmaceutical/biotechnology sector. Advanced undergraduate coursework or practical familiarity/working knowledge in biological sciences and organic chemistry is recommended.

Status: Pharmacology
Status: Patient Safety
IntermediateCourse7 hours

Featured reviews

EK

5.0Reviewed Aug 6, 2024

excellent overview, very concise yet full of practical and useful information

PV

5.0Reviewed Aug 3, 2024

The Course is very useful to those interested in understanding the principles of Pre-clinical Safety. I completed the course quickly in three sittings due to my prior exposure to this area.

All reviews

Showing: 5 of 5

David Mallick
5.0
Reviewed May 8, 2025
Panduranga Rao Varada
5.0
Reviewed Aug 3, 2024
Elaina Kenyon
5.0
Reviewed Aug 7, 2024
Andrea Ujevic
5.0
Reviewed Mar 23, 2025
DHAKSHINESWAR S
5.0
Reviewed Feb 18, 2025